Argus
•
Aug 26, 2026
PODD: Lowering target price to $157.00
Summary
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use.
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Repligen Corporation
Sep 03, 2026
•
RGEN
DXCM: Lowering target price to $26.00
Sep 02, 2026
•
DXCM, TRUP
TFX: Raising target price to $148.00
Sep 02, 2026
•
TFX
RMD: Lowering target price to $255.00
Sep 02, 2026
•
RMD
TNDM: What does Argus have to say about TNDM?
Sep 02, 2026
•
TNDM
